July 28 Is World Hepatitis Day: Eliminate Hepatitis
Project Inform; Posted Jul 28, 12:28 p.m. ET
Around the world and around the U.S. organizations and individuals come together on this day to raise awareness of the global burden of viral hepatitis and to influence change.
HIV Remission News From IAS 2017
Richard Jefferys, Treatment Action Group; Posted Jul 28, 11:35 a.m. ET
Treatment Action Group's Richard Jefferys provides a comprehensive overview of HIV remission presentations at the 9th International AIDS Society Conference on HIV Science.
HIV, Hepatitis C and the Hope for Health Equity
Ashley Brown, AIDS Foundation of Chicago; Posted Jul 28, 11:01 a.m. ET
Peter McLoyd doesn't care what you think of him. From addiction to advocacy, his story has been defined by overcoming obstacles.
Life After Diagnosis
Nakeisa Brown, HIVE; Posted Jul 27, 4:27 p.m. ET
"Through sharing my story, I want to reduce the stigma in our lives and show others that there is truly life after HIV diagnosis," Nakeisa Brown writes.
Everyone living with HIV has a story to tell. Find out how to share your own experiences in one or both of the series below, which feature the writings of readers like you.
Regardless of where or how it happened, the day you received your HIV-positive diagnosis was likely among the most intense days you'll ever live through. Some of TheBody.com's readers have generously shared their experiences -- to reflect on how they've changed, and so that others would know that they too can survive, and even thrive, following that fateful day. How did you get through it?
Many types of medications can save or improve lives, but they can also have unintended consequences. For some people living with HIV, taking meds can be a complicated cycle -- and for others, a Sunday stroll. Medication side effects can be mild or life altering, horrible or even pleasurable; some people living with HIV never experience any at all. It seems like everyone's got a story about side effects. What's yours?
More People With HIV Have the Virus Under Control
U.S. Centers for Disease Control and Prevention; Posted Jul 27, 1:59 p.m. ET
Improved access to testing and treatment saves lives, and is helping prevent new infections, but too many people living with HIV are still not getting the care and treatment they need.
We Demanded U Equals U! We Demanded the Truth and We Got It in IAS 2017
Maria T. Mejia, AVAC: Global Advocacy for HIV Prevention; Posted Jul 27, 12:43 p.m. ET
"As patients and advocates of others, I know that by educating ourselves and others we take the control back," Maria Mejia writes. "We have to be proactive with our health and fight."
Snapshot From IAS 2017
AVAC: Global Advocacy for HIV Prevention; Posted Jul 27, 11:58 a.m. ET
"There is good news and bad news, often in the same story," AVAC writes.
Trump's Military Transgender Ban Draws Condemnation From HIV Organizations
Myles Helfand and Ken Stockwell, TheBody.com; Posted Jul 26, 5:53 p.m. ET
A series of tweets from U.S. President Donald J. Trump on July 26 unexpectedly and dramatically appeared to upend the country's policy on transgender people serving in the military.
My Health Tracker can help you organize your HIV treatment information privately and securely in one place. This way, you can take better charge over your health, and you and your doctor can have even more productive conversations about your treatment.
Registration takes only a couple of minutes, requires no personal info, and you'll be able to pick up where you left off at any time.
British Columbia Researchers Study HIV Treatment Interruptions and Their Consequences
Sean R. Hosein, Canadian AIDS Treatment Information Exchange; Posted Jul 26, 2:40 p.m. ET
Researchers found that nearly 40% of study participants interrupted their first regimen at least once and about 50% of treatment interruptions occurred about a year after antiretroviral therapy had been initiated.
Darunavir/Cobicistat/FTC/TAF: 24-Week Interim Results From Phase 3 Switch Study
Simon Collins, HIV i-Base; Posted Jul 26, 2:22 p.m. ET
Planned 24-week interim results from a 48-week phase 3 study were presented at IAS 2017 and showed that switching to this fixed-dose combination maintained undetectable viral load.
Celebrate U=U! What Undetectable = Untransmittable Means for the HIV Community
Charles Sanchez, TheBody.com; Posted Jul 26, 1:30 p.m. ET
Members of the worldwide HIV community express their views on U=U and how it has affected their lives.
Phase 3 Results With Bictegravir -- A New Integrase Inhibitor Combined With FTC/TAF
HIV i-Base; Posted Jul 25, 5:22 p.m. ET
Two studies presented at IAS 2017 showed bictegravir to be very similar in efficacy to dolutegravir with slight differences in the formulations linked to the background NRTIs in the fixed-dose combinations.
>> Browse Older Featured Stories